Urinary Incontinence Device Market: By Product Type (Urinary Catheters, Electrical Stimulation Devices, Vaginal Slings, Pessary, Artificial Urinary Sphincters, and Others), By Category (External Urinary Incontinence Devices and Internal Urinary Incontinence Devices), By Incontinence Type (Stress Incontinence, Overflow Incontinence, Urge Incontinence, and Functional Incontinence), By End User (Hospital, Clinics, and Others), and Geography

Urinary Incontinence Device Market size was valued at USD 3,183.2 million in 2022 and is poised to grow at a significant CAGR of 5.8% from 2023-2029. The market for urinary incontinence treatment devices has undergone detailed investigation in components because of the negative health and financial effects of urinary incontinence (UI), which is the involuntary or abnormal loss of urine that is typically accompanied by symptoms of the lower urinary tract (LUTS). Urinary incontinence is thought to afflict 500 million individuals worldwide, and the prevalence rises markedly with advancing age. Urinary incontinence can be brought on by a number of conditions, including urinary tract infections, weakened pelvic floor muscles and urethral sphincters, menopause, pregnancy, delivery, and post-radical prostatectomy surgery in males. Overactive bladder affects about 12% of both men and women, and the incidence rises with age, according to the International Continence Society. Major advances in the market for UI treatment devices are being driven by the obvious morbidity of UI and its consequent influence on the lowered quality of life.

A major factor influencing the market for UI treatment devices is the high frequency of UI in geriatric and female patients. After the age of 80, both sexes are equally affected, as seen in high blood pressure and depression. Long-term care patients' increasing hospitalization rate is a major factor in the market for UI therapeutic devices' ongoing technical improvements. Behavioral and pharmaceutical therapies, which are first-line treatments for the care of UI, have advanced during the past couple of decades. Because they are inexpensive and don't interfere with surgical procedures, mechanical devices, in particular, have become very popular for treating stress urinary incontinence (SUI) in women. Pelvic floor muscle training (PFMT) has become a reliable and safe first-line treatment for women. Pessaries are one of the most important mechanical products on the market. The market for UI treatment devices is being driven by the rising sales of various mechanical devices, such as vaginal support prostheses for the treatment of SUI in female patients. Among patient-perceived treatments, PFMT is attracting interest. Despite the fact that vaginal support devices are anticipated to be important in UI, they do not always treat the symptoms.

New modern gadgets are now prominently displayed. In this sense, intravaginal pelvic floor electrostimulation devices are becoming more and more accepted in therapeutic settings, resulting in consistent revenue streams for market participants in UI therapy products. Numerous research has reaffirmed its low risk of negative effects. Additionally, research on the quality of life is investigating the efficacy of UI treatment for various forms of UI. The lack of awareness about the devices and their advantages and also lack of ease of availability is the main restraint to the growth of the market.  

Urinary Incontinence Device Market Key Developments:

• In December 2021, Surgical Product Developer Caldera Medical has announced the launch of the new Desara TVez for stress urinary incontinence In November 2020, BladderCell launched a bioelectric treatment clinical study for urinary incontinence.
• In May 2020, Rigicon launched two new artificial urinary sphincter models: ContiClassic Artificial Urinary Sphincter and ContiReflex Artificial Urinary Sphincter.